Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain

[1]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[2]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[3]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[4]  R. Dhir,et al.  Splicing Factor Prp8 Interacts With NES(AR) and Regulates Androgen Receptor in Prostate Cancer Cells. , 2015, Molecular endocrinology.

[5]  S. Gambhir,et al.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. , 2015, Cancer research.

[6]  Y. Dong,et al.  Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents , 2015, Oncotarget.

[7]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[8]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[9]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[10]  Shihua Sun,et al.  Mechanisms of the androgen receptor splicing in prostate cancer cells , 2014, Oncogene.

[11]  H. Xu,et al.  Androgen receptor: structure, role in prostate cancer and drug discovery , 2014, Acta Pharmacologica Sinica.

[12]  J. Luo,et al.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects , 2014, Oncogene.

[13]  S. Plymate,et al.  The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer , 2014, Hormones and Cancer.

[14]  Zhiyong Guo,et al.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy , 2014, Oncotarget.

[15]  Long Yu,et al.  Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants , 2014, Cell reports.

[16]  S. Plymate,et al.  Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit , 2013, Clinical Cancer Research.

[17]  E. Wiemer,et al.  Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. , 2013, European journal of cancer.

[18]  Jun Luo,et al.  Decoding the androgen receptor splice variants , 2013, Translational andrology and urology.

[19]  R. Andersen,et al.  An androgen receptor N-terminal domain antagonist for treating prostate cancer. , 2013, The Journal of clinical investigation.

[20]  Shihua Sun,et al.  Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors , 2013, Oncotarget.

[21]  D. Generali,et al.  Enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[22]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[23]  F. Claessens,et al.  Evidence for DNA-Binding Domain–Ligand-Binding Domain Communications in the Androgen Receptor , 2012, Molecular and Cellular Biology.

[24]  Yingming Li,et al.  Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal* , 2012, The Journal of Biological Chemistry.

[25]  R. Vessella,et al.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer. , 2012, Cancer research.

[26]  R. Vessella,et al.  AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression , 2011, Oncogene.

[27]  M. Galigniana,et al.  FKBP51 and FKBP52 in signaling and disease , 2011, Trends in Endocrinology & Metabolism.

[28]  W. Isaacs,et al.  A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities , 2011, The Prostate.

[29]  D. Tindall,et al.  Alternatively spliced androgen receptor variants. , 2011, Endocrine-related cancer.

[30]  N. Bander,et al.  Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. , 2011, Cancer research.

[31]  Zhiyong Guo,et al.  Novel Membrane-associated Androgen Receptor Splice Variant Potentiates Proliferative and Survival Responses in Prostate Cancer Cells* , 2011, The Journal of Biological Chemistry.

[32]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[33]  P. Stattin,et al.  Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival , 2011, PloS one.

[34]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[35]  Lawrence B. Gardner,et al.  Nonsense-Mediated RNA Decay Regulation by Cellular Stress: Implications for Tumorigenesis , 2010, Molecular Cancer Research.

[36]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[37]  S. Dhanasekaran,et al.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. , 2009, Cancer research.

[38]  L. Butler,et al.  The contribution of different androgen receptor domains to receptor dimerization and signaling. , 2008, Molecular endocrinology.

[39]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[40]  Frank Claessens,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas Diverse roles of androgen receptor (AR) domains in AR-mediated signaling , 2022 .

[41]  D. Tindall,et al.  Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells* , 2006, Journal of Biological Chemistry.

[42]  L. Maquat.  Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics , 2004, Nature Reviews Molecular Cell Biology.

[43]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[44]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Matusik,et al.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.

[46]  H. Gronemeyer,et al.  Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH2-terminal Domain* , 1999, The Journal of Biological Chemistry.

[47]  Minoru Yoshida,et al.  CRM1 is responsible for intracellular transport mediated by the nuclear export signal , 1997, Nature.

[48]  J. Boyd,et al.  Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. , 1995, Cancer research.

[49]  R. Tsien,et al.  Heat-stable inhibitors of cAMP-dependent protein kinase carry a nuclear export signal. , 1994, The Journal of biological chemistry.

[50]  P. Dijck,et al.  Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments , 1992, Molecular and Cellular Endocrinology.

[51]  H. Akil,et al.  Localization of the 90-kDa heat shock protein-binding site within the hormone-binding domain of the glucocorticoid receptor by peptide competition. , 1991, The Journal of biological chemistry.

[52]  K. Yamamoto,et al.  Two signals mediate hormone‐dependent nuclear localization of the glucocorticoid receptor. , 1987, The EMBO journal.

[53]  L. Sas.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration‑Resistant Prostate Cancer , 2016 .

[54]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[55]  Majid I. Alsagabi,et al.  Molecular and Cellular Pathobiology Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression , 2011 .

[56]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[57]  D. Chopin,et al.  Constitutive activation of the androgen receptor by a point mutation in the hinge region: A new mechanism for androgen‐independent growth in prostate cancer , 2004, International journal of cancer.

[58]  Zhou Wang,et al.  Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. , 2003, The Journal of biological chemistry.

[59]  K. Yamamoto,et al.  Glucocorticoid receptor mutants that are constitutive activators of transcriptional enhancement , 1987, Nature.